Author | Xiao Yu Periodically, major pharmaceutical media and authoritative journals summarize the development of Antibody-Drug Conjugates (ADCs). Recently, a review on ADCs published by the internationally renowned journal ACS was particularly eye-catching. As a member of CAS (a division of the American Chemical Society), Janet M. Sasso’s team innovatively utilized patents and articles related … Read more
Payload The early developed ADCs used FDA-approved anticancer agent small molecule payloads, such as DM1 and vincristine, but these drugs have poor toxicity. Due to the large size of ADCs, it is estimated that only about 2% of ADCs are effectively internalized, thus more toxic payloads have been developed as ADC payloads, most of which … Read more
1 Introduction Antibody-drug conjugates (ADC) are an emerging technology that selectively targets cancer cells to overcome the limitations of chemotherapy.ADC binds to antigens, especially those overexpressed on the surface of cancer cells, reducing side effects caused by nonspecific targeting and improving the therapeutic index. The idealADC efficacy relies entirely on several physicochemical factors, such as … Read more
This conference is themed “Innovative Processes, Achieving the Future of the Pharmaceutical Industry,” featuring one keynote session and three parallel sessions, gathering over 50 professional speakers from the fields of antibodies, ADCs, GLP-1, and peptides. It focuses on downstream processes and advanced separation and purification techniques, discussing the future of the pharmaceutical industry! Known as … Read more
Antibody Antibodies have been analyzed by X-ray crystallography, revealing that Ig consists of four polypeptide chains connected by varying numbers of interchain disulfide bonds. Ig can form a “Y” shaped structure, known as an Ig monomer, which is the basic unit of antibodies. Basic Unit of Antibody The primary antibody specifically recognizes and binds to … Read more
Introduction Antibody-drug conjugates (ADC) are formed by linking monoclonal antibodies that target specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin (brand name: Mylotarg)) was approved for the treatment of CD33-positive acute … Read more
Introduction The design of clinically successful ADCs depends not only on the potency of the payload and its attachment points, the stability of the linker, and effective drug release, but also on the choice of antibodies and bioconjugation technology. Over the past decade, all FDA-approved ADCs have existed in the form of heterogeneous mixtures of … Read more
Since the first ADC drug Mylotarg® (gemtuzumab ozogamicin) was approved by the FDA in 2000, as of December 2021, a total of 14 ADC drugs have been approved globally for hematological malignancies and solid tumors, and currently, there are over 100 ADC candidates at various stages of clinical trials. Recently, the journal Signal Transduction and … Read more
▉ Introduction Antibody-drug conjugates (ADCs) are currently developing rapidly, utilizing antibodies to selectively deliver cytotoxic drugs to tumor sites. As of May 2021, the U.S. Food and Drug Administration (FDA) has approved 10 ADCs, including Adcetris®, Kadcyla®, Besponsa®, Mylotarg®, Polivy®, Padcev®, Enhertu®, Trodvy®, Blenrep®, and Zynlonta™ for use as monotherapy or in combination for the … Read more
Previous Reviews 2023 Overview of Antibody Drug Industry Development History of Monoclonal Antibodies, This Article is Enough! Brief Discussion on the Mechanism of Action and Advantages/Disadvantages of Antibodies How to Name Monoclonal Antibodies, Read This! Magic Bullet – ADC Antibody-drug conjugates (ADC) are a class of targeted biological agents composed of an antibody, a linker, … Read more